A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Completed · Phase 2 · NCT04623775
Conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $305,835
- U.S. investigators named
- 14
- Sites paid
- 15
- Planned or actual enrollment
- 468
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (biological), Relatlimab (biological), Carboplatin (drug), Cisplatin (drug), Paclitaxel (drug), Nab-Paclitaxel (drug), Pemetrexed (drug)
- Dates
- Started 2021-02-17; completion 2026-05-06
- Results posted
- Yes
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
From ClinicalTrials.gov, last updated 2026-06-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $305,835 in research payments for this study in 2025 (15 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sai-hong I Ou, MD Hematology & Oncology · Orange, CA
- Ayed O. Ayed, M.D. Hematology & Oncology · Jacksonville, FL
- Vamsidhar Velcheti, MD Hematology & Oncology · Jacksonville, FL
- Adam D. Lye, M.D. Hematology & Oncology · Louisville, KY
- Christian A. Thomas, MD Hematology & Oncology · Westbrook, ME
- Ralph J. Hauke, MD Hematology & Oncology · Omaha, NE
- Kenneth D. Nahum, D.O. Hematology & Oncology · Howell, NJ
- Rajwanth Veluswamy, MD Medical Oncology · New York, NY
- Jennifer L. Leddon Hematology & Oncology · Cincinnati, OH
- Samuel J. Kerr, M.D. Hematology & Oncology · Lancaster, PA
- Stephen H. Dyar JR., MD Hematology & Oncology · Greenville, SC
- Xuezhong Yang Hematology & Oncology · Greenville, SC
- Robert Droder, M.D. Hematology & Oncology · Tyler, TX
- Arvind Chaudhry, MD Hematology & Oncology · Spokane, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UC Healthcare System $68,767
- New England Cancer Specialists $49,302
- NYU Langone Hospitals - Tisch Hospitals Clinical Labs $32,255
- Lancaster General Hospital, PA $29,396
- Oncology Hematology West P.c. Dba Nebraska Cancer Specialists $28,334
- Bon Secours Mercy Health Inc $28,131
- Regional Cancer Care Associates $18,100
- Uci Health Fountain Valley $11,880
- Bon Secours Mercy Health, Inc $10,850
- Norton Hospitals, Inc, KY $10,082
- Cancer Specialists, Llc $8,646
- Medical Oncology Associates, Ps $3,375
- University of Cincinnati Physicians Company, Llc $3,233
- University of Texas Health Science Center at Tyler, TX $2,581
- Maine Center for Cancer Medicine $905
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.